First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
Federica Giugliano, Edoardo Crimini, Paolo Tarantino, Paola Zagami, Jacopo Uliano, Chiara Corti, Dario Trapani, Giuseppe Curigliano, Paolo A. Ascierto
Topics & Concepts
MedicineVemurafenibNivolumabIpilimumabPembrolizumabAtezolizumabMelanomaOncologyClinical trialMetastatic melanomaAdverse effectInternal medicinePopulationImmunotherapyTargeted therapyCancer researchCancerEnvironmental healthMelanoma and MAPK PathwaysCAR-T cell therapy researchColorectal Cancer Treatments and Studies